

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

September 7, 2023

To Shareholders,

Company Name Renascience Inc.

Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

Notice of Publication of Article on PAI-1 Inhibitor in Nature

The Company has been developing RS5614, a novel plasminogen activator inhibitor 1 (PAI-1) inhibitor, in the fields of oncology and aging-related diseases in collaboration with Tohoku University and several other universities and medical institutions. The September 7 issue of Nature, an international, comprehensive scientific journal (printed and online edition), published an article publicizing RS5614 in the area of cancer and aging-related diseases as "A KIDNEY DISEASE DRUG HELPS FIGHT CANCER AND AGEING" (a part of Nature Index Cancer).

Article URL: <https://www.nature.com/articles/d42473-023-00207-4>

End